Lymphoma Research Foundation Presents 'Ask The Doctor'

Do you have lymphoma or care for someone who does? Do you live in the Washington D.C. area?

On Monday Sept. 16, the Lymphoma Research Foundation is presenting "Updates on Lymphoma and Treatment Options" at Washington Marriot Wardman Park, featuring Bruce D. Cheson, MD., FACP, FAAAS, professor of medicine at Georgetown University, as well as Deputy Chief of the Division of Hematology-Oncology and Head of Hematology Lombardi Comprehensive Cancer Center at Georgetown University Hospital.

Beginning at 6:30 p.m., Dr. Cheson will discuss lymphoma, the latest treatment options and research updates, followed by an "Ask the Doctor" question and answer session.

The event is free to attend, but you do have to register.

More information on the event and registration is available by clicking here.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap